ContributorsPublishersAdvertisers

Scientists find new drug that slows down Parkinson’s disease

Knowridge Science Report
Knowridge Science Report
 2021-11-28
https://img.particlenews.com/image.php?url=0uzlkh_0d8GHL3H00

In a recent study published in Nature Communications, researchers found potential new treatments that could slow the progression of Parkinson’s disease.

They found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain.

The study is from Rush University. One author is Kalipada Pahan, Ph.D.

Lewy bodies are hallmarks of Parkinson’s disease, the most common movement disorder affecting about 1.2 million people in the United States and Canada.

Currently, there are no treatments that slow the progression of Parkinson’s disease—they only treat the symptoms.

Lewy bodies are also linked to the development of Lewy body dementia and a rare neurological disorder called multiple system atrophy (MSA).

In the study, the team developed the new drugs known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD).

The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson’s disease.

The treatments also improved the mice’s gait, balance, and other motor functions.

The team says if these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders.

If you care about Parkinson’s disease, please read studies about simple eye test could help detect Parkinson’s disease early and findings of these two types of dementia linked to Parkinson’s disease.

For more information about Parkinson’s disease, please see recent studies about this prostate disease drug may help lower risk of Parkinson’s disease and results showing that these vitamins may help prevent Parkinson’s disease.

Copyright © 2021 Knowridge Science Report. All rights reserved.

Comments / 1

Comments / 0